Cowen & Co. Gives a Buy Rating to MyoKardia Inc


Cowen & Co. analyst Ritu Baral assigned a Buy rating to MyoKardia Inc (NASDAQ: MYOK) on May 21 and set a price target of $73. The company’s shares closed yesterday at $50.35.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 35.4% and a 57.2% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.

MyoKardia Inc has an analyst consensus of Strong Buy, with a price target consensus of $73.50.

See today’s analyst top recommended stocks >>

Based on MyoKardia Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $17.82 million. In comparison, last year the company had a GAAP net loss of $11.55 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

MyoKardia, Inc. is a biopharmaceutical company. It engages in the discovery, development, and commercialization of targeted therapies for the treatment of cardiovascular diseases. The company focuses on the treatment of heritable cardiomyopathies, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts